Biomerica(US:BMRA) Globenewswire·2026-02-18 13:19Core Insights - Biomerica, Inc. has received approval from Vietnam's Hanoi Department of Health for its EZ Detect™ colorectal disease at-home screening test, marking a significant step in the company's global expansion into Southeast Asia [1][2][11] Group 1: Product Overview - EZ Detect™ is an FDA-cleared two-minute at-home screening test designed to detect early warning signs of colorectal cancer and other colorectal diseases [2][7] - The test identifies occult blood in stool, which is a critical early indicator of colorectal diseases, including cancer [8] - The test is user-friendly, requiring no special preparation or handling of stool, and can be completed privately at home [8][9] Group 2: Market Opportunity - Colorectal cancer is a significant public health issue in Vietnam, with 16,835 new cases reported in 2022, making it the fourth most common cancer in the country [3] - The five-year survival rate for colorectal cancer in Vietnam is only 45%, compared to 91% in the United States when detected early [3][10] - The global market for colorectal cancer screening is substantial, with approximately 1.93 million new cases and over 900,000 deaths worldwide in 2022, and these figures are expected to rise significantly by 2050 [5] Group 3: Strategic Importance - The approval of EZ Detect™ represents a milestone for Biomerica's strategic entry into Southeast Asia's rapidly growing healthcare market, which has over 680 million people and increasing healthcare spending [2][11] - The company aims to work with a major healthcare distributor in Vietnam to ensure widespread availability of the product through various sales channels [1][11] - This approval serves as a template for potential expansion into other Southeast Asian markets, emphasizing the importance of accessible at-home screening tests [11]